BioPredictive Library - FibroTest Publications

FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?

Expert review of molecular diagnostics

Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V

2005 Expert Rev. Mol. Diagn. Volume 5 Issue 1

PubMed 15723588 DOI 10.1586/14737159.5.1.15

Review FibroTest ActiTest Reliability HCV HBV Metabolic Diseases Alcohol Fibrosis Activity/Inflammation Portal Hypertension

Among the noninvasive alternatives to liver biopsy, several studies have demonstrated the predictive value and superior benefit/risk ratio to biopsy of two combinations of simple serum biochemical markers in patients infected with hepatitis B and C virus. These include FibroTest (BioPredictive) for the quantitative assessment of fibrosis, and ActiTest (BioPredictive) for the quantitative assessment of necroinflammatory activity (HCV-FibroSURE, LabCorp). The possible causes of false negatives and positives are also better identified. These tests, which are now available in 12 countries, can facilitate the screening and management of the most frequent liver diseases.

Citation Reference:
Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev. Mol. Diagn. 2005;5:1.